Holen Sie sich die Stockscreener-App
0.0002
33.64%
-0.0601
Schlusskurs vom Vortag:
$0.0603
Offen:
$0.0002
24-Stunden-Volumen:
1,061
Relative Volume:
66.00
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-17.66M
KGV:
-0.000029
EPS:
-6.8879
Netto-Cashflow:
$-9.32M
1W Leistung:
-33.64%
1M Leistung:
-57.01%
6M Leistung:
-93.93%
1J Leistung:
-85.81%
1-Tages-Spanne:
$0.0002
$0.0002
1-Wochen-Bereich:
$0.0002
$0.0002
52-Wochen-Spanne:
$0.0002
$0.0002
Paxmedica Inc Stock (PXMD) Company Profile
Vergleichen Sie PXMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PXMD
Paxmedica Inc
|
0.0002 | 0 | 0 | -17.66M | -9.32M | -6.8879 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Paxmedica Inc Aktie (PXMD) Neueste Nachrichten
Contrasting Calliditas Therapeutics AB (publ) (NASDAQ:CALT) & PaxMedica (NASDAQ:PXMD) - Defense World
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
Comparing Intra-Cellular Therapies (NASDAQ:ITCI) and PaxMedica (NASDAQ:PXMD) - Defense World
Kuvatris Therapeutics Renames, Cancels Shares Amid Restructuring - AInvest
PaxMedica Renames to Kuvatris, Cancels Shares - TipRanks
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
PaxMedica announces board resignations amid transition By Investing.com - Investing.com Canada
PaxMedica announces board resignations amid transition - Investing.com Australia
PaxMedica Announces Board Chairman Resignation Amid Transition - TipRanks
PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data - ACCESS Newswire
PaxMedica Announces Resignation of Key Executives - TipRanks
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection - ACCESS Newswire
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions - ACCESS Newswire
Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc. - ACCESS Newswire
PaxMedica Secures Immediate Exercise of Warrants - ACCESS Newswire
BioMedNewsBreaks – PaxMedica Inc. (PXMD) Secures Patent Approval in China for Autism Treatment - Financial Content
Autism Prevalence Surges Globally, Raising Concerns Among Healthcare Experts - FinancialContent
BioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K | Dow Theory Letters - FinancialContent
BioMedNewsBreaks — PaxMedica Inc. (PXMD) Intensifying Efforts to Achieve Significant Program Milestones - FinancialContent
Researchers Say Brain ‘Overgrowth’ Could Contribute to Autism Development - FinancialContent
Silicon Valley - FinancialContent
PaxMedica (NASDAQ: PXMD) Seeking to Qualify for Neglected Tropical Disease Priority Review Voucher - Barchart.com
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 - Yahoo Finance
PXMD Stock Price and Chart — OTC:PXMD - TradingView
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast - Yahoo Finance
As Autism Cases Rise, Biopharma Springs Into Action - BioSpace
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101 - GlobeNewswire
PaxMedica Receives Emergency Request for IV Suramin from - GlobeNewswire
Why Is PaxMedica (PXMD) Stock Up 93% Today? - InvestorPlace
PaxMedica Achieves Key Milestone in the Development of - GlobeNewswire
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments - GlobeNewswire
PaxMedica Accelerates RSU Vesting for Top Executives - TipRanks
PaxMedica (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals with ASD - The Globe and Mail
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman - StreetInsider
PaxMedica (NASDAQ: PXMD) Closes on Public Offering Reaching Estimated $7M - The Globe and Mail
Penny Stocks To Buy? 5 To Watch Right Now - PennyStocks.com
PaxMedica News of FDA Type-B Meeting Shared in Audio Broadcast - Yahoo Finance
Why Is PaxMedica (PXMD) Stock Down 40% Today? - InvestorPlace
PaxMedica Releases Q3 2023 Financial Report, Corporate Update - Yahoo Finance
What's Going On With PaxMedica Stock Today? - Benzinga
What LIFW, PXMD, and NVOS have in common - StocksToTrade
PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal - Yahoo Finance
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV) - GlobeNewswire
PaxMedica (NASDAQ: PXMD) Reports on 1-for-17 Reverse Stock Split - The Globe and Mail
PaxMedica Announces 1-for-17 Reverse Stock Split - Yahoo Finance
Thinking about buying stock in Nextplay Technologies, ABVC Biopharma, PaxMedica, Mustang Bio, or NXU Inc.? - MarketScreener
Why Is PaxMedica (PXMD) Stock Up Today? - TradingView
PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023 - Yahoo Finance
PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update - Yahoo Finance
PaxMedica seeks SAHPRA approval to initiate ASD therapy trial - Clinical Trials Arena
Finanzdaten der Paxmedica Inc-Aktie (PXMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.96%
1.09%
Kapitalisierung:
|
Volumen (24h):